Proactive Investors - Run By Investors For Investors

Motif Bio PLC says it is in the advanced stages of concluding a proposed placing to institutional and other investors

It said the net proceeds of the proposed placing, when taken together with its existing cash resources are expected to be sufficient to fund the business beyond its meeting with the US FDA
Cash raising
Motif Bio said: “Whilst there can be no certainty that the Proposed Placing will proceed, nor as to the quantum, pricing, or timing of any such placing the Board is seeking to conclude the process shortly"

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) has confirmed that it needs to raise additional capital in the near term and said it is in the advanced stages of concluding a proposed placing of new ordinary shares to institutional and other investors.

The AIM-listed clinical-stage biopharmaceutical company, specialising in developing novel antibiotics, said the net proceeds of the proposed placing, when taken together with its existing cash resources are expected to be sufficient to fund the business beyond its meeting with the US Food & Drug Administration (FDA) scheduled for 3 May 2019.

READ: Motif Bio surges as US FDA agrees to a meeting to discuss new drug application for novel antibiotic iclaprim

At that meeting, Motif Bio will discuss the Complete Response Letter received in respect of the company's New Drug Application (NDA) for its lead novel antibiotic, iclaprim, which said additional data was needed.

The company said it expects to be able to provide guidance as to a route to approval for iclaprim upon receipt of the minutes from this meeting, which would typically be approximately 30 days from the meeting date.

The group added that assuming a viable route to approval, it is expected that further additional funds will be required to resubmit an NDA and reach a new approval date.

Motif Bio concluded: “Whilst there can be no certainty that the Proposed Placing will proceed, nor as to the quantum, pricing, or timing of any such placing the Board is seeking to conclude the process shortly and will update shareholders accordingly.”

In mid-morning trading, Motif Bio shares were 4.6% lower at 7.50p.

View full MTFB profile View Profile

Motif Bio PLC Timeline

Newswire
May 07 2019

Related Articles

1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use